Current Pipeline

February 2019

Present & Future Product Lines

ATI01 – NSCL Cancer

First-in-class metabolic-targeted therapy

ATI02 – Pancreatic Cancer

First-in-class metabolic-targeted therapy

ATI03 – Ovarian Cancer

First-in-class metabolic-targeted therapy

ATI04 – Colon Cancer

First-in-class metabolic-targeted therapy